When was Bosutinib launched in the country?

Bosutinib is an innovative oral tyrosine kinase inhibitor. The original drug has not yet received marketing approval in the Chinese mainland market, and therefore cannot be included in the domestic medical insurance system. For domestic patients, obtaining original drugs requires formal overseas channels or clinical trial channels, and this restriction affects patient accessibility and economic burden to a certain extent. In contrast, bosutinib is more mature in other regions around the world. The original drug is sold in Europe, Turkey, Switzerland and other countries, and has been included in local clinical guidelines for the treatment of chronic myelogenous leukemia.

In addition to the original drug, some developing and Asian countries have produced generic versions of bosutinib. For example, generic drugs in the Indian market maintain the same active ingredients and dosage forms of the original drugs, but are relatively cheap, providing an affordable alternative for overseas or cross-border patients. These generic drugs have been approved by the local drug regulatory authorities to ensure that the quality and efficacy of the drugs are basically the same as the original drugs. In clinical use, generic drugs have been proven to achieve similar molecular response rates and disease control effects, becoming an important treatment avenue for patients who cannot directly obtain original drugs.

Although it is not yet on the market in China, as the demand for targeted treatment of chronic myelogenous leukemia (CML) increases, bosutinib's clinical data, global marketing experience and real-world use by patients are attracting the attention of more doctors and patients. In the future, if original drugs or generic drugs enter the domestic market, it will help enrich CML treatment options and provide new treatment options for patients who cannot tolerate other TKIs. In addition, overseas marketing experience also provides reference for domestic policy formulation, including dosage regimens, drug resistance management and safety monitoring strategies, helping clinicians to better design individualized treatment plans for patients.

Reference materials:https://go.drugbank.com/drugs/DB06616